USV Launches Empagliflozin Range Under Xenia Brand
Written By : Dr. Nandita Mohan
Published On 2025-04-02 06:53 GMT | Update On 2025-04-02 07:23 GMT
Advertisement
USV Pvt. Ltd., a leader in diabetes care, has announced the launch of its Xenia brand range in India, following the patent expiry of Empagliflozin.
The Xenia range includes five key products: Xenia 10 and Xenia 25 as monotherapies, Xenia M 12.5/500 and Xenia M 12.5/1000 ER with Metformin, and Xenia ST 25 combined with Sitagliptin.
Priced competitively, Xenia aims to make advanced diabetes care affordable.
- Xenia 10, containing Empagliflozin 10 mg, is priced at ₹12.5 per tablet.
- Xenia 25, containing Empagliflozin 25 mg, is priced at ₹16.39 per tablet.
- Xenia M 12.5/500, combining Empagliflozin 12.5 mg + Metformin 500 mg, is priced at ₹14 per tablet.
- Xenia M 12.5/1000 ER, combining Empagliflozin 12.5 mg + Metformin 1000 mg ER, is priced at ₹16.5 per tablet.
- Xenia ST 25, a fixed-dose combination of Empagliflozin 25 mg + Sitagliptin 100 mg, is priced at ₹22.02 per tablet.
The Xenia range is available across India, including on e-pharmacies.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.